BASF picks up omega-3 maker; Sigma dislikes Pfizer distributing direct to pharmacies;

> Zhejiang Hisun Pharmaceutical has a deal to commercially manufacture Celsion's heat-activated liposomal encapsulation of doxorubicin, used for the treatment of various cancers. Story

> BASF has bought Equateq, which has a manufacturing plant in Scotland with 47 employees where its makes highly concentrated omega-3 fatty acids for the pharmaceutical industry. Item

> The drug wholesaler Sigma Pharmaceuticals is raising concerns in Australia that a policy requiring drugs to be available within 24 hours is in jeopardy if companies follow Pfizer's lead in bypassing wholesalers and delivering drugs directly to pharmacies. Story

> Tibet Pharmaceuticals ($TBET), which manufactures traditional Tibetan medications, has an agreement with wholesaler Anhui Taihe Pharmaceutical Group, which has a network across 16 provinces and municipalities in China. Announcement

> India's top drug regulator is being investigated for letting pharmaceutical manufacturers, including some of the world's largest, go to market with drugs with little or no clinical testing. Story

> Jubilant HollisterStier has nailed down 5-year agreements to manufacture and distribute two products for Lantheus Medical Imaging. Item

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.